Search results for "CIRRHOSIS"

showing 10 items of 964 documents

Prevalence of Autoantibodies to the p53 Protein in Autoimmune Hepatitis

2003

The target antigens of anti-nuclear autoantibodies in autoimmune hepatitis (AIH) are poorly characterised. Since antibodies to the p53 nuclear protein have been reported in various autoimmune diseases, we have assessed the prevalence of these antibodies in patients with AIH (n = 45), primary biliary cirrhosis (n = 60), hepatitis B (n = 22), hepatitis C (n = 55), and in a control group of subjects with various non-liver diseases (n = 56). A significant proportion of patients with AIH (31%) had elevated levels of autoantibodies to the p53 protein. In contrast, the prevalence of these antibodies in primary biliary cirrhosis (8%) and viral hepatitis (6%) was similar to that in the control group…

MaleHepatitisAutoimmune diseasebusiness.industryImmunologyAutoantibodyAutoimmune hepatitisHepatitis CMiddle AgedHepatitis Bmedicine.diseasedigestive system diseasesHepatitis AutoimmunePrimary biliary cirrhosisimmune system diseasesImmunologymedicineHumansImmunology and AllergyFemaleTumor Suppressor Protein p53businessViral hepatitisAutoantibodiesAutoimmunity
researchProduct

Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci

2012

Background & Aims: A limited number of genetic risk factors have been reported in primary sclerosing cholangitis (PSC). To discover further genetic susceptibility factors for PSC, we followed up on,a second tier of single nucleotide polymorphisms (SNPs) from a genome-wide association study (GWAS). Methods: We analyzed 45 SNPs in 1221 PSC cases and 3508 controls. The association results from the replication analysis and the original GWAS (715 PSC cases and 2962 controls) were combined in a meta-analysis comprising 1936 PSC cases and 6470 controls. We performed an analysis of bile microbial community composition in 39 PSC patients by 16S rRNA sequencing. Results: Seventeen SNPs representing 1…

MaleLinkage disequilibriumendocrine system diseasesGenome-wide association studyPrimary biliary cirrhosisGenotypeBLOOD-GROUPBileChildPOPULATIONAged 80 and overGeneticseducation.field_of_studyPrimary sclerosing cholangitisdigestive oral and skin physiologyMiddle AgedFucosyltransferasesChild PreschoolDISEASESFemaleNeprilysinReceptors Tumor Necrosis Factor Member 14B-LYMPHOCYTEAdultRiskGenome-wide association studyAdolescentGenotypeSUSCEPTIBILITY LOCIFUT2Cholangitis SclerosingPopulationT-LYMPHOCYTE ATTENUATORSingle-nucleotide polymorphismBiologyPolymorphism Single Nucleotidedigestive systemArticlePrimary sclerosing cholangitisGenetic predispositionmedicineImmunogeneticsHumansGenetic Predisposition to DiseaseeducationMETAANALYSISAgedNON-SECRETOR STATUSHepatologymedicine.diseaseGENEdigestive system diseasesSingle nucleotide polymorphismGenetic LociImmunology
researchProduct

Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis

2017

OBJECTIVES Non-invasive fibrosis scores are widely used to identify/exclude advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). However, these scores were principally developed and validated in patients aged between 35 and 65 years of age. The objective of this study was to assess the effect of age on the performance of non-invasive fibrosis tests in NAFLD. METHODS Patients were recruited from European specialist hepatology clinics. The cohort was divided into five age-based groups: ≤35 (n=74), 36-45 (n=96), 46-55 (n=197), 56-64 (n=191), and ≥65 years (n=76), and the performance of the aspartate aminotransferase (AST)/alanine transaminase (ALT) ratio, fibrosis 4 (F…

MaleLiver CirrhosisPathologyBiopsyPredictive Value of TestAspartate AminotransferasesGastroenterology0302 clinical medicineFibrosisReference ValuesNon-alcoholic Fatty Liver DiseaseArea under curvePrevalenceMedicineReference ValueAge FactorConfoundingAge FactorsGastroenterologyAlanine TransaminaseFalse Positive ReactionMiddle Aged3. Good healthLiver030220 oncology & carcinogenesisPredictive value of testsArea Under Curve030211 gastroenterology & hepatologyFemaleLiver pathologyHumanAdultmedicine.medical_specialtyLiver Cirrhosi610 Medicine & healthdigestive system03 medical and health sciencesPredictive Value of TestsInternal medicineHumansFalse Positive ReactionsAspartate AminotransferasesAgedHepatologybusiness.industryPlatelet CountNon invasivenutritional and metabolic diseasesAspartate AminotransferaseHepatologymedicine.diseaseFibrosisdigestive system diseasesFatty LiverROC CurveHuman medicinebusinessBiomarkersThe American Journal of Gastroenterology
researchProduct

Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting

2018

International audience; BACKGROUNDS & AIMS: Treating patients with decompensated cirrhosis with direct-acting antiviral (DAA) therapy while on the waiting list for liver transplantation results in substantial improvement of liver function allowing 1 in 4 patients to be removed from the waiting list or delisted, as reported in a previous study promoted by the European Liver and Intestine Transplant Association (ELITA). The aim of this study was to report on clinical outcomes of delisted patients, including mortality risk, hepatocellular carcinoma development and clinical decompensation requiring relisting. METHODS: One hundred and forty-two HCV-positive patients on the liver transplant waiti…

MaleLiver Cirrhosismedicine.medical_specialtyCirrhosisCarcinoma HepatocellularWaiting Listsmedicine.medical_treatment[SDV]Life Sciences [q-bio]Liver transplantationSeverity of Illness IndexAntiviral Agents03 medical and health sciences0302 clinical medicineInternal medicineAscitesmedicineHumansDecompensationChronicdirect-acting antiviralsdirect-acting antiviralHepatologyliver transplantationbusiness.industrydelistingcirrhosisCarcinomaLiver NeoplasmsHepatocellularHepatitis CTransplant Waiting ListHepatitis C ChronicMiddle Agedmedicine.diseaseHepatitis C3. Good healthItaly030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyFemaleLiver functionmedicine.symptombusinesscirrhosi
researchProduct

Consequences of Extended Spectrum Beta-Lactamase-Producing Enterobacteriaceae and Methicillin-Resistant Staphylococcus aureus Carriage in Awaiting Li…

2020

Infections in patients with cirrhosis are associated with liver-related complications (LRCs), especially in patients awaiting liver transplantation (LT). The aim of this study was to evaluate the impact of methicillin-resistant Staphylococcus aureus (MRSA) and extended spectrum beta-lactamase colonization on infections and LRCs for patients on the wait list and on infections after LT. We retrospectively included 250 of 483 patients with cirrhosis who were placed on the wait list for LT from December 2015 to January 2018. These patients were screened for MRSA or extended spectrum beta-lactamase–producing Enterobacteriaceae (ESBLE) at the time of wait-list placement and after LT. Of the patie…

MaleMethicillin-Resistant Staphylococcus aureusmedicine.medical_specialtyCirrhosismedicine.medical_treatmentESBLELiver transplantationmedicine.disease_causeSeverity of Illness Indexbeta-Lactamasesbeta-LactamaseEnd Stage Liver Disease03 medical and health sciencesLiver disease0302 clinical medicineEnterobacteriaceaeRetrospective StudieRisk FactorsInternal medicineSeverity of illnessMedicineHumansAgedRetrospective Studies0303 health sciencesTransplantation[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyHepatology030306 microbiologybusiness.industryRisk FactorcirrhosisEnterobacteriaceae InfectionsRetrospective cohort studyMiddle Agedmedicine.diseaseEnterobacteriaceae InfectionMethicillin-resistant Staphylococcus aureus3. Good healthLiver TransplantationCarriageCohort030211 gastroenterology & hepatologySurgeryfecal carriageFemalebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation SocietyReferences
researchProduct

High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Geno…

2015

BACKGROUND Few direct anti-hepatitis C virus (HCV) agents have been studied in difficult-to-treat null responder and cirrhotic human immunodeficiency virus (HIV)-coinfected patients. Daclatasvir and asunaprevir combined with pegylated interferon/ribavirin (peg-IFN/RBV) have shown promising results in HCV-monoinfected patients. METHODS An open-label, single-arm, phase 2 study was conducted in HIV/HCV genotype 1/4-coinfected patients who were null responders to prior peg-IFN/RBV standard therapy and on a raltegravir-based regimen with HIV RNA <400 copies/mL. They received a 4-week lead-in phase with peg-IFN/RBV, followed by 24 weeks of asunaprevir (100 mg twice daily), daclatasvir (60 mg once…

MaleMicrobiology (medical)medicine.medical_specialtyPyrrolidinesDaclatasvir[SDV]Life Sciences [q-bio]PopulationHIV InfectionsHepacivirusAntiviral AgentsGastroenterologychemistry.chemical_compoundPegylated interferonInternal medicinemedicineHumansdaclatasvireducationasunaprevireducation.field_of_study[ SDV ] Life Sciences [q-bio]Coinfectionbusiness.industryRibavirincirrhosisImidazolesvirus diseasesHIVValineHepatitis C ChronicMiddle AgedRaltegravirmedicine.disease3. Good healthRegimenTreatment OutcomeInfectious DiseaseschemistryImmunologyHCVCoinfectionAsunaprevirFemaleCarbamatesbusinessmedicine.drug
researchProduct

Mitochondrial biogenesis fails in secondary biliary cirrhosis in rats leading to mitochondrial DNA depletion and deletions

2011

Chronic cholestasis is characterizedby mitochondrial dysfunction, associated with loss of mitochondrialmembrane potential, decreased activities of respiratory chaincomplexes, and ATP production. Our aim was to determine themolecular mechanisms that link long-term cholestasis to mitochondrialdysfunction. We studied a model of chronic cholestasis inducedby bile duct ligation in rats. Key sensors and regulators of theenergetic state and mitochondrial biogenesis, mitochondrial DNA(mtDNA)-to-nuclear DNA (nDNA) ratio (mtDNA/nDNA) relativecopy number, mtDNA deletions, and indexes of apoptosis (BAX,BCL-2, and cleaved caspase 3) and cell proliferation (PCNA) wereevaluated. Our results show that long…

MaleMitochondrial DNAPhysiologyMitochondrial TurnoverMitochondrial HepatopathyNF-E2-Related Factor 1Respiratory chainMitochondria LiverProtein Serine-Threonine KinasesMitochondrionBiologyDNA MitochondrialSirtuin 1CholestasisProliferating Cell Nuclear AntigenPhysiology (medical)medicineAnimalsRats Wistarbcl-2-Associated X ProteinCholestasisHepatologyCaspase 3Liver Cirrhosis BiliaryGastroenterologyPyruvate Dehydrogenase Acetyl-Transferring KinaseRNA-Binding ProteinsTFAMmedicine.diseaseGA-Binding Protein Transcription FactorPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaMolecular biologyRatsGenes MitochondrialProto-Oncogene Proteins c-bcl-2Mitochondrial biogenesisChronic DiseaseBile DuctsGene DeletionTranscription FactorsAmerican Journal of Physiology-Gastrointestinal and Liver Physiology
researchProduct

The gene of hepatocyte growth factor is expressed in fat-storing cells of rat liver and is downregulated during cell growth and by transforming growt…

1992

Hepatocyte growth factor (HGF) has been detected in non-parenchymal cells but not in hepatocytes. We performed Northern blot analysis of total RNA extracted from rat hepatocytes, Kupffer cells, endothelial cells and fat-storing (Ito-) cells. Total RNA was extracted from fat-storing cells at different times after isolation and from cells treated with different amounts of transforming growth factor beta. The RNA was hybridized with HGF, fibronectin-, and alpha-actin-specific cDNA probes, consecutively. We found an abundant amount of HGF mRNA in freshly isolated fat-storing cells, but not in other liver cells. The amount of the HGF transcripts decreases significantly in FSC during the time of …

MaleMolecular Sequence DataBiophysicsDown-RegulationCell SeparationLiver Cirrhosis ExperimentalBiochemistryTransforming Growth Factor betaGene expressionmedicineAnimalsNorthern blotGrowth SubstancesMolecular BiologyCells CulturedMessenger RNABase SequencebiologyHepatocyte Growth FactorCell BiologyTransforming growth factor betaBlotting NorthernMolecular biologyActinsFibronectinsRatsBlotmedicine.anatomical_structureAdipose TissueGene Expression RegulationLiverHepatocytebiology.proteinHepatocyte growth factorDNA Probesmedicine.drugTransforming growth factorBiochemical and Biophysical Research Communications
researchProduct

Bile duct epithelia as target cells in primary biliary cirrhosis and primary sclerosing cholangitis.

1997

Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are chronic autoimmune-mediated diseases of the biliary tree, resulting in a loss of bile ducts. There are morphological features that clearly distinguish them from each other: in PBC, there is overt destruction of the bile ducts with disruption of the basement membrane; in PSC there is abundant periductular fibrosis with shrinkage and subsequent loss of the bile ducts. In order to see if the disparate histopathology is paralleled by different immunohistology we looked at a panel of epitopes on bile duct epithelia especially to see if biliary epithelial cells may present as targets for cell mediated immune response. In…

MalePathologymedicine.medical_specialtyBiliary cirrhosisLymphocyteT-LymphocytesCholangitis SclerosingBiologydigestive systemEpitopeEpitheliumPathology and Forensic MedicinePrimary sclerosing cholangitisAutoimmune DiseasesPrimary biliary cirrhosisImmune systemAntigenAntigens CDHLA AntigensmedicineHumansMolecular BiologyImmunity CellularBile ductLiver Cirrhosis BiliaryCell BiologyGeneral Medicinemedicine.diseasedigestive system diseasesmedicine.anatomical_structureCytokinesFemaleBile DuctsVirchows Archiv : an international journal of pathology
researchProduct

Adult to Adult Living Donor Liver Transplantation in Recipients with Low MELD: A Strategy Intended to Overcome Donor Shortage

2020

Recent series have demonstrated advantages of living donor over deceased donor liver transplantation, with particular benefit for those with low model for end-stage liver disease score. The logic underlying the transplantation of patients before they become too sick is intuitive. It reduces mortality and drop outs from the waiting list and makes transplant surgery less demanding. Those principles have to be balanced with donor safety and transplant benefit for the recipient avoiding early, futile transplantation. The authors report a case of adult to adult right lobe living donor liver transplantation performed for a recipient affected by primary biliary cirrhosis with MELD score of 15, in …

MalePhysiologymedicine.medical_treatmentLiver transplantationSeverity of Illness IndexLiver diseasePostoperative Complications0302 clinical medicinePrimary biliary cirrhosisTransplant surgeryLiving DonorsLiver Transplantation.Liver resectionLiver Cirrhosis BiliaryGastroenterologyCone-Beam Computed TomographyMiddle AgedTreatment Outcomesurgical procedures operativeItalyLiver030220 oncology & carcinogenesisFemaleRisk Adjustment030211 gastroenterology & hepatologyLiving donor liver transplantationHumanAdultmedicine.medical_specialtyTissue and Organ ProcurementClinical Decision-MakingTime-to-TreatmentEnd Stage Liver Disease03 medical and health sciencesInternal medicineSeverity of illnessmedicineHepatectomyHumansIntensive care medicineLiver transplantationbusiness.industryLiving donor liver transplantationHepatologymedicine.diseasePleural EffusionTransplantationSurgeryPostoperative Complicationbusiness
researchProduct